Precision Optics (POCI) Q3 2025 earnings summary

Executive summary

• Q3 FY2025 revenue was $4.2M, down from $5.2M in Q3 FY2024, with a net loss of $2.1M ($0.30/share), mainly due to production challenges and engineering resource reallocation.

• Gross margin dropped to 10% from 35.5% year-over-year, reflecting low yields and under-absorption of engineering resources.

• Adjusted EBITDA was negative $1.3M, versus positive $52,000 a year ago.

• Record production backlog, driven by a new aerospace agreement with minimum annual purchase commitments of nearly $4M for 2025 and 2026.

• Unity Imaging Platform launched, expected to accelerate endoscopic device development and customer timelines by 6–12 months.

Financial highlights

• Production revenue grew to $3.3M from $3.0M year-over-year, while engineering revenue fell to $0.9M from $2.3M.

• Cash and cash equivalents increased to $2.55M at March 31, 2025, from $0.41M at June 30, 2024, due to equity raises.

• SG&A expenses rose to $2.2M for the quarter, up from $1.9M year-over-year.

• R&D expenses increased to $211,000 for the quarter and $930,000 for nine months, reflecting investment in new technologies.

• Finished Products and Assemblies revenue dropped 42.3% for the quarter due to lower demand and order timing.

Outlook and guidance

• Q4 revenue is expected to reach $6M, with a return to positive or break-even adjusted EBITDA.

• Minimum annual purchase commitments of nearly $4M secured for 2025 and 2026 from aerospace customer.

• Second production line for the cystoscope is planned for the first half of fiscal 2026.

• Management expects available cash, operations, and credit access to be sufficient for at least 12 months.

• Customer pipeline expected to expand as projects transition to production.